Akademska digitalna zbirka SLovenije - logo
E-resources
Full text
Peer reviewed Open access
  • Impact of Aspirin on clinic...
    Casadei-Gardini, Andrea; Rovesti, Giulia; Dadduzio, Vincenzo; Vivaldi, Caterina; Lai, Eleonora; Lonardi, Sara; Fornaro, Lorenzo; Pretta, Andrea; Zagonel, Vittorina; Bernardini, Laura; Astara, Giorgio; D'Amico, Francesco E.; Masi, Gianluca; Rimini, Margherita; Scartozzi, Mario; Cascinu, Stefano

    HPB (Oxford, England), June 2021, 2021-06-00, 20210601, Volume: 23, Issue: 6
    Journal Article

    The aim of our retrospective study is to evaluate the prognostic significance of aspirin in patients with advanced HCC treated with sorafenib. 304 patients with HCC,consecutively treated with sorafenib from May 2007 to September 2018, were included in the clinical study. Of Them 93 patients token aspirin. Progression-free survival (PFS)and overall survival (OS)were estimated with the Kaplan–Meier method and compared with the log-rank test. The concomitant use of sorafenib and aspirin was associated with a median OS of 18.3 months compared to 8.8 months of patients who did not receive aspirin (HR 0.57; P < 0.0001). The concomitant use of sorafenib and aspirin was associated with a median PFS of 7.3 months compared to 3.0 months of patients who did not receive aspirin (HR 0.61; P = 0.0003). In the multivariate analysis, the use of aspirin maintained an independent prognostic value for OS(HR 0.61; P = 0.0013). In second line the concomitant use of regorafenib and aspirin was associated with a median OS of 16.9 months compared to 8.0 months of patients who did not receive aspirin (HR 0.30; P = 0.02). Globally, our data seem to suggest that aspirin use may improve the clinical outcome of patients with advanced hepatocellular carcinoma receiving sorafenib and regorafenib.